🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Alan Menter

Baylor Medical Center at Garland

ORCID: 0000-0002-9314-0007
Immunology and MicrobiologyMedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
0.945Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Journal of the European Academy of Dermatology and Venereology(2022)10.1111/jdv.18167
Top 21%
0.945DataRank
Top 21%23 citations

E. Daudén, Sascha Gerdes, Mark Lebwohl, Alan Menter, C. Leonardi +11 more

Papers

Driven by 4 papers — median percentile 79. Top paper: “A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)”.

A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S)

Journal of Investigative Dermatology(2020)10.1016/j.jid.2020.01.025
N/A
3.0DataRank · unranked
96 citations

Daniel B. Shin, Kristina Callis Duffin, April Armstrong, Andrew Blauvelt, Stephen K. Tyring +16 more

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

Journal of the European Academy of Dermatology and Venereology(2022)10.1111/jdv.18167
Top 21%
0.945DataRank
Top 21%23 citations

E. Daudén, Sascha Gerdes, Mark Lebwohl, Alan Menter, C. Leonardi +11 more

Ustekinumab for the treatment of psoriatic arthritis

Expert Review of Clinical Immunology(2014)10.1586/1744666x.2014.878649
N/A
0.406DataRank · unranked
14 citations

Alan Menter, Jay Wofford

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Journal of the American Academy of Dermatology(2020)10.1016/j.jaad.2020.09.047
N/A
0DataRank · unranked
27 citations

Craig L. Leonardi, Nehal N. Mehta, Alice B. Gottlieb, Alan M. Mendelsohn, Jeff Parno +3 more